SBRT-SG 05 (ClinicalTrials.gov Identifier: NCT02192788) is a collaborative (SBRT-SG, GICOR and SEOR) prospective multicenter phase II trial testing SBRT and hormone therapy (HT) in oligometastatic prostate cancer patients. The hypothesis is that SBRT can control the macroscopic disease and HT the microscopic one, as well as to test in hormone-sensitive (HS) patients the pause of the HT after biochemical control is achieved and that Castration Resistant prostate cancer (CRPC) is not radioresistant prostate cancer, and SBRT can delay new systemic treatments.